OMNY Health, the leading healthcare ecosystem for compliant real-world data insights at scale, and Scipher Medicine, which has the world’s largest immunology clinico-transcriptomics data set and is focused on advancing precision medicine with proprietary AI network biology solutions, announced a partnership to advance precision medicine efforts for immunology.
This collaboration...
Prudentia Sciences, an AI-powered technology platform for life sciences announced its public launch, supported by $7 million in funding. The funding round was led by GV, with participation from Iaso Ventures and Virtue. The company aims to empower biopharma companies to accelerate drug pipelines and maximize return on investment, ensuring healthcare innovations...
Tempus AI, Inc, a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration with Genialis, the RNA-biomarker company. The multi-year agreement allows Genialis to leverage Tempus’ multimodal dataset to develop new RNA-based algorithms across cancer types.
Clinical care for cancer patients is...
This collaboration combines real world clinical EMR data from a large footprint of cancer centers with research grade multi-omics data collected at key treatment timepoints. These data and linked biobanked samples support discovery of novel biomarkers that will inform treatment decision-making and improve patient outcomes.
The ONCare Alliance, representing 32...
Deciphex, a leader in AI-powered digital pathology, has closed its Series C financing, raising $32.3 million to address the acute global pathology crisis. Led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories, IRRUS Investments, HBAN Medtech Syndicate and Nextsteps Capital, the funding will...
PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody-Drug-Conjugate (ADC) collaboration while also expanding their existing $260M AI Lab collaboration, which itself was built upon a successful Generative Chemistry partnership.
The teams will leverage PostEra's AI platform, Proton,...
Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading...
iBio, Inc., an AI-driven innovator of precision antibody immunotherapies, announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio’s proprietary technology stack and was designed for...
Partnership advances better neurovascular patient care by delivering timely insights to clinicians and improving clinical workflows
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, and Avicenna.AI, a leading provider of AI-based medical imaging solutions, announced that Viz.ai is integrating Avicenna.AI’s CINA-iPE and CINA-ASPECTS tools into the Viz.ai...
COTA Inc., a leader in real-world data and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s...
